Welcome to LookChem.com Sign In|Join Free

CAS

  • or

761440-65-7

Post Buying Request

761440-65-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

761440-65-7 Usage

General Description

1-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine is a chemical compound with a complex molecular structure. It consists of a piperazine ring with a 4-methyl substitution and a piperidin-4-yl group connected to a 3-methoxy-4-nitrophenyl moiety. This chemical compound has potential pharmaceutical applications and may be used in the development of new drugs for various medical conditions. The intricate structure of 1-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine makes it a promising candidate for further research and exploration in the field of medicinal chemistry and drug discovery.

Check Digit Verification of cas no

The CAS Registry Mumber 761440-65-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,1,4,4 and 0 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 761440-65:
(8*7)+(7*6)+(6*1)+(5*4)+(4*4)+(3*0)+(2*6)+(1*5)=157
157 % 10 = 7
So 761440-65-7 is a valid CAS Registry Number.

761440-65-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[1-(3-Methoxy-4-nitrophenyl)-4-piperidinyl]-4-methylpiperazine

1.2 Other means of identification

Product number -
Other names Burgodin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:761440-65-7 SDS

761440-65-7Relevant articles and documents

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

Finlay, M. Raymond V.,Barton, Peter,Bickerton, Sue,Bista, Michal,Colclough, Nicola,Cross, Darren A. E.,Evans, Laura,Floc’h, Nicolas,Gregson, Clare,Guérot, Carine M.,Hargreaves, David,Kang, Xiaoming,Lenz, Eva M.,Li, Xu,Liu, Yi,Lorthioir, Olivier,Martin, Matthew J.,McKerrecher, Darren,McWhirter, Claire,O’Neill, Daniel,Orme, Jonathan P.,Mosallanejad, Arash,Rahi, Amar,Smith, Paul D.,Talbot, Verity,Ward, Richard A.,Wrigley, Gail,Wylot, Marta,Xue, Lin,Yao, Tieguang,Ye, Yang,Zhao, Xiliang

, p. 13704 - 13718 (2021/09/28)

The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including osimertinib, have been approved for clinical use. Resistance to these therapies has emerged due to a variety of molecular events including the C797S mutation which renders third-generation C797-targeting covalent EGFR inhibitors considerably less potent against the target due to the loss of the key covalent-bond-forming residue. We describe the medicinal chemistry optimization of a biochemically potent but modestly cell-active, reversible EGFR inhibitor starting point with sub-optimal physicochemical properties. These studies culminated in the identification of compound 12 that showed improved cell potency, oral exposure, andin vivoactivity in clinically relevant EGFR-mutant-driven disease models, including an Exon19 deletion/T790M/C797S triple-mutant mouse xenograft model.

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor

Groendyke, Brian J.,Nabet, Behnam,Mohardt, Mikaela L.,Zhang, Haisheng,Peng, Ke,Koide, Eriko,Coffey, Calvin R.,Che, Jianwei,Scott, David A.,Bass, Adam J.,Gray, Nathanael S.

supporting information, p. 30 - 38 (2021/01/11)

Focal adhesion kinase (FAK) is a tyrosine kinase with prominent roles in protein scaffolding, migration, angiogenesis, and anchorage-independent cell survival and is an attractive target for the development of cancer therapeutics. However, current FAK inhibitors display dual kinase inhibition and/or significant activity on several kinases. Although multitargeted activity is at times therapeutically advantageous, such behavior can also lead to toxicity and confound chemical-biology studies. We report a novel series of small molecules based on a tricyclic pyrimidothiazolodiazepinone core that displays both high potency and selectivity for FAK. Structure-activity relationship (SAR) studies explored modifications to the thiazole, diazepinone, and aniline "tail,"which identified lead compound BJG-03-025. BJG-03-025 displays potent biochemical FAK inhibition (IC50 = 20 nM), excellent kinome selectivity, activity in 3D-culture breast and gastric cancer models, and favorable pharmacokinetic properties in mice. BJG-03-025 is a valuable chemical probe for evaluation of FAK-dependent biology.

Preparation method of ALK inhibitor Brigatinib

-

Paragraph 0051-0054, (2020/06/02)

The invention relates to the technical field of medicines, and relates to a preparation method of a medicine ALK inhibitor AP26113. The method comprises the following steps: (1) carrying out substitution reaction of aromatic amine on 2,4,5-trichloropyrimi

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 761440-65-7